62 results about "Anti viral immunity" patented technology

The present invention relates to compositions and methods for enhancing an immune response, for example to a vaccine, by combining the administration of oxygen (O2 gas), an adenosine pathway antagonist and / or an HIF-1α antagonist, and / or inhibitors of enzymes that produce or generate adenosine with the administration of the vaccine to the patient.The present invention also relates to methods of inducing or enhancing immune responses, methods of treating subjects having a tumor, methods of ablating or killing tumor cells and methods of disrupting the blood supply to a tumor, comprising administering oxygen alone or in combination with therapeutic agents that prevent inhibition of anti-tumor T cells. Tumor defense-resistant immune cells, anti-viral immune cells, and methods of their production are also disclosed.

Hemagglutination assays and hemagglutination inhibition assays were introduced in medical and virology practice more than 60 years ago. Since then, these assays have become important tools for measuring concentrations and strengths of viral cultures, the efficacy of the anti-viral immunization, and for studying the neutralizing capacity of virus-specific antibodies. The present invention comprises an improved hemagglutination inhibition assay (HAI), with at least about a 10-fold increase in sensitivity versus the traditional the HAI, to provide more accurate measurements of components in, for example, fluids from the in vitro MIMIC® system when assessing the effects of anti-viral vaccines (e.g., for seasonal influenza).

The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1 / MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.

Virus vectors, virus particles, and methods and uses of screening for, detecting, analyzing and determining amounts of virus antibody, or neutralizing antibody activity of samples are provided. Such virus vectors, virus particles, and methods and uses are applicable to a broad range of virus types, such as lentiviruses, adenovirus, and adeno-associated virus (AAV) serotypes. Methods and uses include virus antibody screening, such as anti-virus immunoglobulins screened for, detected, analyzed and amounts determined

A sensor chip for detecting an immune response against an influenza virus, the sensor chip including a substrate having a surface and a plurality of hemagglutinin polypeptides bound to discrete locations on the surface of the substrate, each hemagglutinin polypeptide having a hemagglutinin epitope. Detection devices containing the sensor chip and methods of detecting influenza immune responses are also described herein.

A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.

The present invention relates to the use of non-pathogenic multi-cmponent viral particles in vaccines whcih utilize heat shock proteins to enhance the anti-viral immune response. The multi-component viral particles are covalently conjugated to one or more species of "javelin", where javelins are molecules which form non-covalent associatiosn with heat shock proteins. In view of the role of heat shock proteins in the recognition, by the immune system, of antigens, the addition of a javelin "tether" to a multi-component viral particle facilitates complex formation between the particle and a heat shock protein and hence promotes development of an immune reaction to the particle, without requiring the identification of specific epitopes. In addition, the present invention provides for methods of preventing or ameliorating viral infections comprising administering a "javelinized" multi-component viral particle vaccine to a subject at risk of contracting a viral infection or who has already been infected. Because of the diversity of epitopes in the multi-component viral particles, a single vaccine formulation may be used to promote immunity toward multiple viral strains in subjects having various histocompatibility profiles.

The invention discloses a compound of a hepatitis B virus antigen and lewis oligosaccharide and a preparation method and application thereof. The compound is prepared mainly through combination of a core hepatitis B virus antigen and lewis oligosaccharides-x. The preparation method comprises the following steps: preparing a conjugate of the core hepatitis B virus antigen and streptavidin, and combining the conjugate with (lewis oligosaccharides-x)-sodium polyacrylate-biotin through high affinity of the streptavidin and the biotin, thereby preparing the compound of the hepatitis B virus antigen and the lewis oligosaccharide. The compound enhances the capability of recognition of a immune system to the hepatitis B virus due to the active targeting of dendritic cells through the high affinity of the lewis oligosaccharides-x and DC-SIGN, can activate specific CTL responses and induce strong anti-viral immunity, and can be applied in the preparation of vaccines for treatment of the hepatitis B.

The present invention involves a new viral immunotherapy drug complex, and in particular, a viral immunotherapy drug complex for persistent hepatitis B infection. The present drug consists of antiviral drugs, immunoregulating drugs and a recombinant hepatitis B vaccine, for use in treating hepatitis B and in particular chronic hepatitis B infections. Antiviral drugs of the described drug complex are selected among α-IFN and nucleosides; the immunoregulating drugs are selected from among GM-CSF and similar.

The invention discloses a group of substituted benzoheterocycle amine derivatives and a preparation method and related application thereof as an IMPDH (inosine monophosphate dehydrogenase) inhibitor. The IMPDH inhibitor has good application prospects in virus resistance, immunosuppression, tumor resistance, bacterium resistance, parasite resistance and the like. In the invention, a new-structure IMPDH inhibitor shown by the formula (I) is obtained through the design, synthesis and activity screening study on an active compound targeting IMPDH, and a foundation is laid for the development and application of the compounds as the medicines and medicinal compositions thereof with related effects such as virus resistance, tumor resistance, immunosuppression and the like.

The invention discloses an antisense oligonucleotide targeting a COVID-19 new coronavirus, a chimeric molecule and application thereof. Antisense nucleic acids targeting S protein and E protein are respectively designed and synthesized according to RNA (Ribonucleic Acid) sequences of spike protein and envelope protein of COVID-19 new coronavirus, and part of the antisense nucleic acids are further conjugated with a functional group 2'-5' adenine of targeting ribonuclease L to obtain the chimeric molecule. The antisense oligonucleoside nucleic acid and the antisense nucleic acid chimeric molecule (NATAC molecule) thereof provided by the invention can obviously reduce the expression level of target RNA (Ribonucleic Acid), meanwhile, obviously activate the expression of ribonuclease L, beta-interferon and interleukin 6 in cells, show obvious drug effect advantages and can effectively activate potential antiviral immunity in the cells. Therefore, the antisense oligonucleotide or the chimeric molecule provided by the invention can be used as a nucleic acid drug for preventing or treating COVID-19 new coronavirus infection.

The invention provides a preparation method of microparticles for preventing novel coronavirus and an application, and relates to the field of vaccines. Specifically, the preparation method comprisesthe following steps: 1) constructing recombinant plasmids for overexpression of a spike (S) protein; 2) packaging the recombinant plasmids into lentiviral particles; 3) infecting fibroblasts with thelentiviral particles to obtain tool cells for expressing of S protein; 4) performing X-ray irradiation on the obtained tool cells and a culture solution, and collecting supernatant after radiotherapyto obtain a mixture of required microparticles and apoptotic tool cell debris; and 5) performing centrifuging, concentrating and purifying on the obtained mixture to obtain a vaccine. According to theinvention, the microparticles released by radiotherapy induction tool cells are used as a carrier, so that the antiviral immunity of an organism can be directly activated under the condition of overexpression of the novel coronavirus S protein, and a neutralizing antibody for resisting the novel coronavirus is generated. According to the invention, an organism can be induced to generate a high-level neutralizing antibody immune response, and besides, good biological safety is achieved.

The invention relates to a method for preparing a gene therapy medicine for novel corona virus 2019. The method comprises the following steps: according to an nCoV2019 (novel corona virus 2019) genome, screening an siRNA (small interference ribonucleic acid) sequence with an RNA interference effect, and performing synthesis by using a nucleic acid synthesis method; and preparing synthesized nCoV2019siRNA into lipid nanoparticles LHNPs, and compounding LHNPs or nCoV2019siRNA with a spray, so as to obtain a gene therapy product with inhalation administration. When reaching target cells, siRNA isdegraded since an siRNA antisense strand which is generated under the action of inherent and stress boosted helicase and endonuclease / exonuclease is combined with homologous RNA and / or mRNA (messenger ribonucleic acid). In addition, type-I interferon, IL-6, TNFa (tumor necrosis factor a) and the like can be generated under stimulation of double-strand siRNA and cellular immunity can be mediated,it is known that type-I interferon has antiviral immunity, IL-6 is capable of inducing hyperplasia of immune globulin and T cells, and the TNFa is capable of promoting infection resistance of neutrophile granulocyte, inducing apoptosis of virus infected cells and thus inhibiting virus hyperplasia, so that in addition to virus prevention of RNA interference, antibacterial antiviral immunity of cellfactors, immune cells and immune globulin can be also triggered, and in addition, the medicine can be efficiently and rapidly synthesized, and is easy in short-term application to treatment or prevention.

A diagnostic method for the prediction of the development and control of the effectiveness of the treatment of cardiovascular diseases, in which patient tissue samples are taken, microassay are prepared, specific antiviral immunoglobulins are processed, the number of cells infected by two or more viruses before the beginning of treatment are determined, and the dynamic of the change in the number of infected cells and their interrelationships are established: when the number of cells infected by cytomegalovirus and any other viruses decreases by more than 50±10% in patients without symptoms of cardiovascular pathology, a diagnostic conclusion is high danger of the development of atherosclerosis; if the number of cells infected by cytomegalovirus and any other viruses exceeds 50±10% in patients with demonstrated clinical signs of cardiovascular system pathology, a diagnostic conclusion is drawn of the danger of the development of complications such as arrhythmia, thrombolytic embolism.

Since it was proposed to be a tumor suppressor, QM protein has attracted intensive studies in plants, animals and fungi. So far, however, the function of the QM protein remains unknown. In this investigation, it is found that the shrimp QM gene (designated as PjQM) is significantly up-regulated in virus-resistant shrimp, thereby suggesting that the PjQM is involved in shrimp immunity. The GST pull-down assays show that the PjQM protein interactes with shrimp hemocyanin and myosin, thus indicating that the PjQM protein might participate in prophenoloxidation (proPO) activation system of shrimp immunity. As revealed by the RNAi assays, it is demonstrated for the first time that the QM protein could regulate the activity of phenol oxidase (PO) through interaction with hemocyanin, a key enzyme in the proPO activation system of invertebrate antiviral immunity.

The invention discloses a DNA (deoxyribonucleic acid) segment and applications thereof in constructing an HCV (hepatitis C virus) whole-genome expression animal model. The nucleotide sequence of the DNA segment comprises the following sequentially series connected sequences: an operator gene sequence of bacteria tetracycline drug-resistance operon, an immediate early promoter gene sequence of human macrophage, a gene sequence of HCV whole genome, and a gene sequence of ribozyme shearing the HCV whole genome activity on DNA and / or RNA (ribonucleic acid) level. The DNA segment can be used for constructing a tetracycline or tetracycline derivative-induced HCV whole genome-expressed transgenic animal model. The immunity of the animal model is normal, thereby being capable of producing specific anti-virus immunoreaction aiming at the expression of the HCV, and further being effectively applied to the research on the immunopathogenesis damage mechanism of drug evaluation and virus infection of the HCV vaccine.

The invention discloses a processing method of white tea. The method comprises the following steps: (1) tea picking; (2) cooling; (3) withering; (4) rolling; (5) shaping; (6) stoving; and (7) purification: subjecting crude tea to winnowing and sieving to pick out non-tea impurities so as to obtain a finished product. The method ensures the high quality and efficiency of white tea processing, particularly improves the color, aroma, taste and appearance of ''green leaf yellow-green soup'' of the white tea and improves the quality of leaf bases, increases the yield of prepared tea, and improves the quality of the white tea. The white tea processed by the method is regular in shape; the dried tea is full of pekoe; the snail-shaped tea is similar to silver pearls; the needle-shaped tea is similar to silver needles; the white tea is rich in aroma, pure in taste, lasting in fragrance, mellow in taste and sweet in aftertaste; the tea water is smooth in mouth, yellow green, bright and clear insoup color and durable in brewing; the white tea has the characteristics of high amino acid content and low tea polyphenol content, also contains active enzymes necessary for human body, has good anti-virus immune functions, and can be preserved at normal temperature for 10 years without deterioration.

An agent that stimulates antiviral immunity may be used, for the treatment of cancer. A product comprising an immunostimulant and a vector comprising a transgene that promotes death of neoplastic cells, may also be used for simultaneous, sequential or separate administration in the treatment of cancer.

Compositions and methods are provided, comprising at least one beta-lactam compound selected from the group consisting of cefuroxime, a penicillin, ceftriaxone, clavulanic acid, 6-aminopenicillanic acid (6-APA) and tazobactam, for enhancing T cell mediated immune responses in a subject, such as anti-tumor and anti-viral immune responses.

An approach to genetic vaccine methodology is described. A genetic construction encoding antigenic determinants of a virus is transfected into cells of the vaccinated individuals using a particle acceleration protocol so as to express the viral antigens in healthy cells to produce an immune response to those antigens.

The present invention discloses a processing technology of tea leaves. The processing technology comprises the following steps: (1) tea leaf picking; (2) green leaf cooling; (3) withering; (4) rolling; (5) shaping; (6) drying; and 7) purifying: raw tea is prepared into the finished product by selection by winnowing, screening and non-tea impurity picking out. The processing technology ensures highquality and high efficiency of tea leaf processing, particularly improves color, fragrance, taste and shapes of "green leaf yellow and green liquid" of the tea leaves and quality of leaf bottoms, increases the yield of the prepared tea and improves the quality of the tea leaves. The tea leaves processed by the method are neatly shaped; dry tea is covered with white hairs; spiral-shaped tea is like silver beads; needle tea is like silver needles; the tea leaves are fragrant and mellow in taste, lasting in delicate fragrance, mellow in taste and sweet in aftertaste; tea water is moist in mouthfeel; the tea liquid is yellow, green, bright and clear; and the tea leaves are resistant to brewing for a long time, relatively high in amino acid content and low in tea polyphenol content, at the same time also contain active enzymes necessary for human body, have very good anti-viral immune functions and can be preserved for 10 years under normal temperature without deterioration.

Viral-based vectors are genetically engineered to express inhibitors of the anti-viral immune system (e.g. inhibitors of the type I interferon response) in order to enhance transgene expression. The transgenes may encode antigens or other therapeutic agents.

The invention discloses a processing technology for white tea. The processing technology comprises the following steps: firstly, picking tea leaves; secondly, airing green leaves; thirdly, withering;fourthly, rolling; fifthly, shaping; sixthly, drying; seventhly, purifying: winnowing and screening raw tea and picking out non-tea inclusions to obtain a finished product. According to the processingtechnology disclosed by the invention, high quality and high efficiency of white tea processing are ensured, particularly the qualities of green leaf yellow green soup in color, fragrance, taste, shape and leaf bottom are improved, and the yield of produced tea and the quality of the white tea are improved. The white tea processed by the method disclosed by the invention has the advantages of neat shape, rich fragrance, mellow taste, long last fragrance, mellow flavor, sweet aftertaste, smoothness of tea soup in mouth, yellow and green bright clear soup color and long-time making endurance; dry tea is covered with pekoe, spiral tea resembles silver beads, and needle tea resembles a silver needle; the white tea has the characteristics of higher content of amino acid and low content of teapolyphenol; moreover, the white tea also contains active enzymes essential for a human body, has a good anti-viral immune function and can be preserved at a normal temperature for 10 years without spoilage.

The present invention provides methods for treatment and prevention of Coronavirus Disease 2019 (COVID-19) and any clinical presentations associated with it including Acute Respiratory Distress Syndrome (ARDS), Severe Inflammatory Response Syndrome (SIRS), and / or any state corresponding to a severe acute attack of an inflammatory pathology causing an exacerbation of cytokine storm associated with unregulated oxidative, endoplasmic reticulum, and inflammatory stress mediated cytotoxic effects following the infection with the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) with at least a pharmacologically acceptable trace element, Selenium (Se) containing molecule, or compound, or drug, or injection, or intravenous infusion. This is achieved by administering to a subject, a therapeutically effective amount of at least a pharmacologically acceptable molecule containing Se at an initial high dose followed by reduced, continuous dosing in subsequent treatment so as to employ its antioxidant, cytokine-modulating, antiviral, immune-enhancing, anti-apoptotic, and anticoagulant properties for the treatment and prevention of COVID-19.

The invention discloses a composite for hepatitis B virus core antigen and heat shock protein and a preparation method and application thereof. The composite is combined by the hepatitis B virus core antigen and the glucose-regulated protein 170 through a non-covalent bond, can activate and recognize the specificity CTL of the hepatitis B virus core antigen, induces strong antiviral immunity without any adjuvant, and is not limited by MHC in same species application. The preparation method for the composite is simple, can be used for preparing hepatitis B therapeutic vaccines and has good development and application prospect in the field of hepatitis B immune therapy.

The invention discloses a production method of white tea. The production method comprises the following steps of (1) picking tea leaves; (2) performing fresh leaf airing; (3) performing withering; (4)performing rolling; (5) performing tidying; (6) performing baking; and (7) performing clean substance extraction: performing air separation and sieving on semi-finished tea, and picking out non-tea foreign bodies to obtain finished products. According to the production method disclosed by the invention, superior efficient processing of the white tea is guaranteed, particularly the color, fragrance, taste, shape and leaf base quality of green leaf yellowish green soup of the white tea can be improved, the tea yield is increased, and the quality of the white tea is improved. The white tea processed by the method disclosed by the invention is tidy in shape, dried white tea is covered with white fine long hairs, spiral tea is similar to silver pearls, and needle tea is similar to silver needles; the white tea is rich in fragrance, mellow in taste, long in delicate fragrance, mellow in taste, and sweet in aftertaste; tea soup is smooth after being drunk in mouths, and soup color is yellowish green, bright and clear; and the white tea is resistant to soak, has the characteristics of being high in amino acid content and low in tea polyphenol content, besides, further contains active enzymes necessary by human bodies, has good antiviral immunity functions, and cannot deteriorate after being preserved for 10 years at room temperature.

The invention provides a method for improving the antiviral immunity of fishes. The antiviral immunity of the fishes is enhanced by increasing the expression amount of Bmp8a protein. The invention firstly provides use of the Bmp8a protein, which is application of the Bmp8a protein in the preparation of a product for improving the antiviral immunity of the fishes. According to the method, it is proved that the antiviral capacity of zebra fishes after bmp8a gene knockout is significantly reduced, over-expression of the Bmp8a can significantly up-regulate the expression of antiviral related genessuch as interferon, and it is shown that the Bmp8a plays an important role in the antiviral immunity. Bmp8a mature peptides are injected in the fishes, which enhances the antiviral immunity of the fishes, thereby achieving the purpose of preventing and treating viral diseases of the fishes.